Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Arcus Ventures United States

Arcus Ventures was founded in 2007 and is based in New York City. Arcus Ventures is currently investing from its second fund, which had a first close of $36m in 2014 and is targeting a raise of $100m. The firm typically invests $2-5 million. Arcus invests primarily in the USA but is also open to considering opportunities in Canada.

Website:
http://www.arcusventures.com
Year Founded
2007
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Myoung-Ok Kwon
Venture Partner 

Artiman Ventures

Artiman is a venture capital company founded in 2 and based in Palo Alto California. The firm is currently making investments out of its fourth $2 million fund. The firm makes seed and venture investments into firms ranging from a few hundred thousand to $5 million depending on the stage and financial requirements of the company. The firm has a preference for companies based in Silicon Valley but will consider opportunities globally and looks to make around 5 investments per year.
Website:
www.artiman.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Akhil Saklecha
Managing Director 

Asset Management Ventures

Asset Management Ventures is a private investment firm funded by a single LP and is based in California USA. The firm invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $25K to $1M (usually in equity or convertible notes). For early-stage companies the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company?s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.
Website:
www.assetman.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Capital Structure Preference
Investment Stage Preference
Richard Simoni
Managing Partner 

ASTEC Japan

ASTEC is a Tokyo-based, accelerator-type investment firm focused on company creation and seed-stage investment. We have been solely investing in Japan but now plans to launch a new fund, together with Tokyo-based FinTech Global Capital, that also invests in other geography leveraging our Japan connection, both academic inventions and pharmaceutical companies. ASTEC deeply gets involved with the management of its portfolio companies and represents some of them for BD activities.

Website:
http://www.ut-astec.com/en/index.html
Year Founded
2001
Sector Interest
Biotech Phase of Development
Investment Stage Preference
Mr Takuro Wakabayashi
LinkedIn logo Managing Partner 

Astia Angels

Astia is an organization whose mission is to provide women-led startups access to capital resources and executive leadership. Astia was founded in 2013 and is based in San Francisco California with additional offices in New York New York and London United Kingdom. Astia typically provides access to capital to women-led life science companies through two programs: Astia Venture Lunches and Astia Angels and is in the process of developing a third program: Astia Fund. Companies that apply to Astia Venture Lunches will be vetted by Astia?s Expert Sift process. The selected companies are invited to present to a room of accredited investors: VCs and angels. Companies applying to Astia are also considered by Astia Angels and the investments from Astia Angels are typically under $1 million. Astia is stage agnostic though companies applying should be able to show traction and proof of concept. Companies can be global and must have at least one woman in a leadership position of significant influence and holding equity.
Website:
www.drexler.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Karen Drexler
Founder 
Sharon Vosmek
CEO 
Sara Frankel
Member 

ATEM Capital

ATEM Capital manages evergreen Life Sciences investment fund - Health Square Fund (HSF). HSF acts as a consolidator of capital flows from the Emerging Markets and invests into the biotech innovation hubs of the US/Western Europe. HSF's international team combines big-picture business perspective with decades of investment scientific legal portfolio risk management and operational experience. The fund is audited by a Big-4 firm. Our Advisory Board comprises high-caliber entrepreneurs VC veterans and seasoned Wall Street professionals.
Website:
www.atemcap.com
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Alexey Afanasiev
Executive Partner 
Anton Gopka
CEO General Partner 
Elena Ikhsanova
COO General Partner 

Baird Venture Partners

Baird Venture Partners is the venture and expansion capital arm of Robert W. Baird & Co. The Baird Venture Partners team is based in Chicago Illinois and has around $27 million in total assets under management. In 214 Baird closed a fourth venture capital fund at $185 million. The firm is currently seeking opportunities in the life science sector and while Baird has no strict timeline to make investments the group would invest in a new firm within the next 6-9 months if a compelling opportunity was identified. The firm?s equity investments range from $3-1 million but are typically in the $8-1 million range.The firm will only consider investment into US based firms.
Website:
www.rwbaird.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Momei Qu
Senior Associate 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Priyanka Rohatgi
Director 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Website:
www.bd.com
Investor Type
Sector Interest
Biotech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Albert Lauritano
Director Strategic Technology Partnerships 

BioScience Managers Australia

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Website:
http://www.biosciencemanagers.com/
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Jeremy Curnock Cook
Managing Director 
Amanda Gillon
Investment Analyst 
Matt McNamara
CIO